{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:08:06Z","timestamp":1777486086716,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There have been numerous classification systems to diagnose corresponding myositis subtypes and select appropriate therapeutic measures. However, the lack of a broad consensus on diagnostic criteria has led to clinical uncertainties. The objective of this study was to compare two commonly used dermatomyositis-classification systems regarding their clinical practicability and to point out their specific advantages and disadvantages.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study included 30 patients diagnosed with dermatomyositis at the Charit\u00e9 university hospital, Berlin, Germany from 2010 to 2017. Patient files with complete data and defined historical classifications were enrolled and ENMC (2003) and EULAR\/ACR (2017) criteria retrospectively applied.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>According to the ENMC approach, 14 patients were classified as \"definite\" and 12 as \"probable\" dermatomyositis. One patient exhibited an \"amyopathic dermatomyositis\" and three a \"DM without dermatitis\". Regarding the criteria probability of the EULAR\/ACR set, 16 patients had a \"high\", 13 a \"medium\" and one a \"low probability\". There was a significant difference (p\u2009=\u20090.004) between the subclasses of the ENMC in relation to the EULAR\/ACR score. The agreement between the classification probabilities of \"definite\/high\" (\u03ba\u2009=\u20090.400) and \"possible\/medium\" (\u03ba\u2009=\u20090.324) was fair.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>It is important to find a consensus among the medical disciplines involved and to establish a structured procedure. Future studies with newer approaches are warranted to conclusively decide which system to use for the physician.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42466-021-00159-4","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T01:02:18Z","timestamp":1636938138000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Performance of ENMC and EULAR\/ACR classification systems applied to a single tertiary center cohort of dermatomyositis patients"],"prefix":"10.1186","volume":"3","author":[{"given":"Jan","family":"Zoske","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udo","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Siegert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Kleefeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinna","family":"Preu\u00dfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Stenzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"issue":"9","key":"159_CR1","doi-asserted-by":"publisher","first-page":"715","DOI":"10.7326\/0003-4819-122-9-199505010-00010","volume":"122","author":"PH Plotz","year":"1995","unstructured":"Plotz, P. H., Rider, L. G., Targoff, I. N., Raben, N., O\u2019Hanlon, T. P., & Miller, F. W. (1995). NIH conference. Myositis: Immunologic contributions to understanding cause, pathogenesis, and therapy. Annals of Internal Medicine, 122(9), 715\u2013724. https:\/\/doi.org\/10.7326\/0003-4819-122-9-199505010-00010","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"159_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ccm.2019.05.004","volume":"40","author":"K Long","year":"2019","unstructured":"Long, K., & Danoff, S. K. (2019). Interstitial lung disease in polymyositis and dermatomyositis. Clinics in Chest Medicine, 40(3), 561\u2013572. https:\/\/doi.org\/10.1016\/j.ccm.2019.05.004","journal-title":"Clinics in Chest Medicine"},{"issue":"Suppl 4","key":"159_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/rheumatology\/kel311","volume":"45","author":"IE Lundberg","year":"2006","unstructured":"Lundberg, I. E. (2006). The heart in dermatomyositis and polymyositis. Rheumatology (Oxford), 45(Suppl 4), 18\u201321. https:\/\/doi.org\/10.1093\/rheumatology\/kel311","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"159_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/BF02229868","volume":"13","author":"G Citera","year":"1994","unstructured":"Citera, G., Goni, M. A., Maldonado Cocco, J. A., & Scheines, E. J. (1994). Joint involvement in polymyositis\/dermatomyositis. Clinical Rheumatology, 13(1), 70\u201374. https:\/\/doi.org\/10.1007\/BF02229868","journal-title":"Clinical Rheumatology"},{"issue":"7","key":"159_CR5","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan, A., & Peter, J. B. (1975). Polymyositis and dermatomyositis (first of two parts). The New England Journal of Medicine, 292(7), 344\u2013347. https:\/\/doi.org\/10.1056\/NEJM197502132920706","journal-title":"The New England Journal of Medicine"},{"issue":"8","key":"159_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan, A., & Peter, J. B. (1975). Polymyositis and dermatomyositis (second of two parts). The New England Journal of Medicine, 292(8), 403\u2013407. https:\/\/doi.org\/10.1056\/NEJM197502202920807","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"159_CR7","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s10067-019-04512-6","volume":"38","author":"B Pinto","year":"2019","unstructured":"Pinto, B., Janardana, R., Nadig, R., Mahadevan, A., Bhatt, A. S., Raj, J. M., & Shobha, V. (2019). Comparison of the 2017 EULAR\/ACR criteria with Bohan and Peter criteria for the classification of idiopathic inflammatory myopathies. Clinical Rheumatology, 38(7), 1931\u20131934. https:\/\/doi.org\/10.1007\/s10067-019-04512-6","journal-title":"Clinical Rheumatology"},{"issue":"5","key":"159_CR8","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/WCO.0000000000000740","volume":"32","author":"J Tanboon","year":"2019","unstructured":"Tanboon, J., & Nishino, I. (2019). Classification of idiopathic inflammatory myopathies: Pathology perspectives. Current Opinion in Neurology, 32(5), 704\u2013714. https:\/\/doi.org\/10.1097\/WCO.0000000000000740","journal-title":"Current Opinion in Neurology"},{"issue":"5","key":"159_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","volume":"14","author":"JE Hoogendijk","year":"2004","unstructured":"Hoogendijk, J. E., Amato, A. A., Lecky, B. R., Choy, E. H., Lundberg, I. E., Rose, M. R., Vencovsky, J., de Visser, M., & Hughes, R. A. (2004). 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands.  Neuromuscular Disorders, 14(5), 337\u2013345. https:\/\/doi.org\/10.1016\/j.nmd.2004.02.006","journal-title":"Neuromuscular Disorders"},{"key":"159_CR10","doi-asserted-by":"publisher","unstructured":"Lundberg, I. E., Tjarnlund, A., Bottai, M., Werth, V. P., Pilkington, C., de Visser, M., \u2026, Repository. (2017). 2017 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatology. https:\/\/doi.org\/10.1002\/art.40320","DOI":"10.1002\/art.40320"},{"key":"159_CR11","doi-asserted-by":"publisher","unstructured":"Lundberg, I. E., Tjarnlund, A., Bottai, M., Werth, V. P., Pilkington, C., Visser, M., \u2026, Repository. (2017). 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Annals of the Rheumatic Diseases, 76(12), 1955\u20131964. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211468","DOI":"10.1136\/annrheumdis-2017-211468"},{"issue":"4","key":"159_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11926-018-0726-4","volume":"20","author":"V Leclair","year":"2018","unstructured":"Leclair, V., & Lundberg, I. E. (2018). New myositis classification criteria\u2014What we have learned since Bohan and Peter. Current Rheumatology Reports, 20(4), 18. https:\/\/doi.org\/10.1007\/s11926-018-0726-4","journal-title":"Current Rheumatology Reports"},{"issue":"5","key":"159_CR13","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/rheumatology\/kep355","volume":"49","author":"SM Sultan","year":"2010","unstructured":"Sultan, S. M., & Isenberg, D. A. (2010). Re-classifying myositis. Rheumatology (Oxford), 49(5), 831\u2013833. https:\/\/doi.org\/10.1093\/rheumatology\/kep355","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"159_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11926-018-0733-5","volume":"20","author":"PW Wolstencroft","year":"2018","unstructured":"Wolstencroft, P. W., & Fiorentino, D. F. (2018). Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Current Rheumatology Reports, 20(5), 28. https:\/\/doi.org\/10.1007\/s11926-018-0733-5","journal-title":"Current Rheumatology Reports"},{"issue":"1","key":"159_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/archdermatol.2009.328","volume":"146","author":"MJ Bendewald","year":"2010","unstructured":"Bendewald, M. J., Wetter, D. A., Li, X., & Davis, M. D. (2010). Incidence of dermatomyositis and clinically amyopathic dermatomyositis: A population-based study in Olmsted County, Minnesota.  Archives of Dermatology, 146(1), 26\u201330. https:\/\/doi.org\/10.1001\/archdermatol.2009.328","journal-title":"Archives of Dermatology"},{"key":"159_CR16","doi-asserted-by":"publisher","unstructured":"McCann, L. J., Juggins, A. D., Maillard, S. M., Wedderburn, L. R., Davidson, J. E., Murray, K. J., \u2026, Juvenile Dermatomyositis Research, G. (2006). The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)\u2014Clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford), 45(10), 1255\u20131260. https:\/\/doi.org\/10.1093\/rheumatology\/kel099","DOI":"10.1093\/rheumatology\/kel099"},{"issue":"1","key":"159_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","volume":"30","author":"AL Mammen","year":"2020","unstructured":"Mammen, A. L., Allenbach, Y., Stenzel, W., Benveniste, O., Allenbach, Y., Benveniste, O., De Bleecker, J., Boyer, O., Casciola-Rosen, L., Christopher-Stine, L., Damoiseaux, J., Gitiaux, C., Fujimoto, M., Lamb, J., Landon-Cardinal, O., Lundberg, I. E., Mammen, A., Nishino, I., Radke, J., \u2026 Werth, V. (2020). 239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14\u201316 December 2018. Neuromuscular Disorders, 30(1), 70\u201392. https:\/\/doi.org\/10.1016\/j.nmd.2019.10.005","journal-title":"Neuromuscular Disorders"},{"issue":"1","key":"159_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10067-018-4267-z","volume":"38","author":"E Zampeli","year":"2019","unstructured":"Zampeli, E., Venetsanopoulou, A., Argyropoulou, O. D., Mavragani, C. P., Tektonidou, M. G., Vlachoyiannopoulos, P. G., Tzioufas, A. G., Skopouli, F. N., & Moutsopoulos, H. M. (2019). Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies. Clinical Rheumatology, 38(1), 125\u2013132. https:\/\/doi.org\/10.1007\/s10067-018-4267-z","journal-title":"Clinical Rheumatology"},{"key":"159_CR19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fneur.2016.00064","volume":"7","author":"A Malik","year":"2016","unstructured":"Malik, A., Hayat, G., Kalia, J. S., & Guzman, M. A. (2016). Idiopathic inflammatory myopathies: Clinical approach and management. Frontiers in Neurology, 7, 64. https:\/\/doi.org\/10.3389\/fneur.2016.00064","journal-title":"Frontiers in Neurology"},{"issue":"11","key":"159_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212709","volume":"77","author":"IE Lundberg","year":"2018","unstructured":"Lundberg, I. E., & Tjarnlund, A. (2018). Response to: \u201c2017 EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: Little emphasis on autoantibodies, why?\u201d by Malaviya. Annals of the Rheumatic Diseases, 77(11), e78. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212709","journal-title":"Annals of the Rheumatic Diseases"},{"key":"159_CR21","unstructured":"Web-based Calculator: Classification criteria for idiopathic inflammatory myopathies. Retrieved September 29, 2021, from, http:\/\/www.imm.ki.se\/biostatistics\/calculators\/iim\/"},{"issue":"7","key":"159_CR22","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1111\/1756-185X.13605","volume":"22","author":"X Zhang","year":"2019","unstructured":"Zhang, X., Yang, X., Ji, L., & Zhang, Z. (2019). Validation of 2017 classification criteria for adult and juvenile idiopathic inflammatory myopathies proposed by EULAR\/ACR in Chinese patients. International Journal of Rheumatic Diseases, 22(7), 1278\u20131282. https:\/\/doi.org\/10.1111\/1756-185X.13605","journal-title":"International Journal of Rheumatic Diseases"},{"key":"159_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.12.001","author":"S Barsotti","year":"2019","unstructured":"Barsotti, S., Dastmalchi, M., Notarnicola, A., Leclaire, V., Dani, L., Gheorghe, K., Ekholm, L., Bottai, M., Tj\u00e4rnlund, A., & Lundberg, I. E. (2019). Performance of the new EULAR\/ACR classification criteria for idiopathic inflammatory myopathies (IIM) in a large monocentric IIM cohort. Seminars in Arthritis and Rheumatism. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.12.001","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"1","key":"159_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/joim.12524","volume":"280","author":"IE Lundberg","year":"2016","unstructured":"Lundberg, I. E., Miller, F. W., Tjarnlund, A., & Bottai, M. (2016). Diagnosis and classification of idiopathic inflammatory myopathies. Journal of Internal Medicine, 280(1), 39\u201351. https:\/\/doi.org\/10.1111\/joim.12524","journal-title":"Journal of Internal Medicine"},{"issue":"7","key":"159_CR25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/acr2.11061","volume":"1","author":"Q Luu","year":"2019","unstructured":"Luu, Q., Day, J., Hall, A., Limaye, V., & Major, G. (2019). External validation and evaluation of adding MRI or extended myositis antibody panel to the 2017 EULAR\/ACR myositis classification criteria. ACR Open Rheumatology, 1(7), 462\u2013468. https:\/\/doi.org\/10.1002\/acr2.11061","journal-title":"ACR Open Rheumatology"},{"issue":"7","key":"159_CR26","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamaneurol.2020.0673","volume":"77","author":"M Inoue","year":"2020","unstructured":"Inoue, M., Tanboon, J., Hirakawa, S., Komaki, H., Fukushima, T., Awano, H., Tajima, T., Yamazaki, K., Hayashi, R., Mori, T., Shibuya, K., Yamanoi, T., Yoshimura, H., Ogawa, T., Katayama, A., Sugai, F., Nakayama, Y., Yamaguchi, S., Hayashi, S., \u2026 Nishino, I. (2020). Association of dermatomyositis sine dermatitis with anti-nuclear matrix protein 2 autoantibodies. JAMA Neurology, 77(7), 872\u2013877. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0673","journal-title":"JAMA Neurology"},{"issue":"6","key":"159_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nrneurol.2011.63","volume":"7","author":"AL Mammen","year":"2011","unstructured":"Mammen, A. L. (2011). Autoimmune myopathies: Autoantibodies, phenotypes and pathogenesis. Nature Reviews Neurology, 7(6), 343\u2013354. https:\/\/doi.org\/10.1038\/nrneurol.2011.63","journal-title":"Nature Reviews Neurology"},{"issue":"5","key":"159_CR28","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/WCO.0000000000000376","volume":"29","author":"O Benveniste","year":"2016","unstructured":"Benveniste, O., Stenzel, W., & Allenbach, Y. (2016). Advances in serological diagnostics of inflammatory myopathies. Current Opinion in Neurology, 29(5), 662\u2013673. https:\/\/doi.org\/10.1097\/WCO.0000000000000376","journal-title":"Current Opinion in Neurology"},{"issue":"12","key":"159_CR29","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","volume":"75","author":"K Mariampillai","year":"2018","unstructured":"Mariampillai, K., Granger, B., Amelin, D., Guiguet, M., Hachulla, E., Maurier, F., Meyer, A., Tohm\u00e9, A., Charuel, J.-C., Musset, L., Allenbach, Y., & Benveniste, O. (2018). Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurology, 75(12), 1528\u20131537. https:\/\/doi.org\/10.1001\/jamaneurol.2018.2598","journal-title":"JAMA Neurology"},{"issue":"1","key":"159_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis, J. R., & Koch, G. G. (1977). The measurement of observer agreement for categorical data. Biometrics, 33(1), 159\u2013174.","journal-title":"Biometrics"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-021-00159-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-021-00159-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-021-00159-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T01:03:06Z","timestamp":1636938186000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-021-00159-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["159"],"URL":"https:\/\/doi.org\/10.1186\/s42466-021-00159-4","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,15]]},"assertion":[{"value":"6 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the appropriate ethics committee (EA4\/053\/17) and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JZ, US, ES, FK, CP, WS declare that they have no competing interests. KH received financial reimbursement for consulting and advisory board activities and travel support to attend scientific meetings by Akcea Therapeuticals Inc., Alnylam Pharmaceuticals Inc., Takeda Pharmaceutical Inc., Pfizer Pharmaceuticals Inc. and Swedish Orphan Biovitrum Inc.. KH further received research funding by the foundation Charit\u00e9 (BIH clinical fellow), Alnylam Pharmaceuticals Inc., and Pfizer Pharmaceuticals, all outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}